Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus
A breakthrough GLP-1 receptor agonist FDA-approved for weight management and type 2 diabetes. Demonstrated consistent 15% body weight reduction in clinical trials with cardiovascular benefits.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~7 days
1.7–2.4 mg weekly
Subcutaneous injection or oral (Rybelsus)
Mechanism of Action
Mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite via central nervous system signaling.
Key Research Areas
Frequently Asked Questions
What is Semaglutide?▾
How does Semaglutide work?▾
What is the recommended dosage for Semaglutide?▾
What is the half-life of Semaglutide?▾
Is Semaglutide FDA approved?▾
Research Disclaimer
The information provided about Semaglutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.